Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01311687 · ADVERSE EVENTS

Adverse events

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study · Source last updated 2018-10-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Adverse events occurred during the study; they are not necessarily caused by treatment. Serious events are not interchangeable with severe/grade 3–4 events. These safety populations may differ from efficacy populations.

Collection time frame
From first dose of study drug through to 30 days after the last dose as of the end of the study (29 August 2017); maximum time on treatment was 297, 269, and 239 weeks in the Pomalidomide + LD-Dex, HD-Dex, and cross-over groups respectively.
Other-event reporting threshold
5%
Participants affected / participants at risk, as reported
Safety groupSerious eventsOther eventsDeaths
Pomalidomide Plus Low-Dose Dexamethasone

Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.

195 / 300291 / 300252 / 300
High-Dose Dexamethasone

Participants received 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression, or until cross-over to pomalidomide. Data are up to the time of cross-over.

80 / 150143 / 150124 / 150
HD-Dex / Pomalidomide

Participants initially randomized to high-dose dexamethasone (HD-Dex) crossed over to receive 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle, with or without low-dose dexamethasone (40 mg for participants ≤ 75 years or 20 mg for participants \> 75 years of age, administered orally once per day on Days 1, 8, 15, and 22 of each 28-day cycle) at the discretion of the investigator. Data include AEs that occurred after cross-over to pomalidomide.

4 / 1111 / 118 / 11

Group identifiers: EG000: Pomalidomide Plus Low-Dose Dexamethasone · EG001: High-Dose Dexamethasone · EG002: HD-Dex / Pomalidomide

Serious adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      10
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      7
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Anaemia
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Blood disorder
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      19
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Febrile neutropenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Haemorrhagic anaemia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Hyperviscosity syndrome
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      10
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Neutropenia
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Pancytopenia
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      6
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Thrombocytopenia
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Angina pectoris
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      7
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Atrial fibrillation
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Atrial flutter
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Atrial tachycardia

Other reported adverse events

Event terms and counts are source-reported; expand to read more. A reporting threshold may omit less frequent events.

  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      159
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      77
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      11
    term
    Anaemia
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      40
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      8
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Leukopenia
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      13
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      8
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Lymphopenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      155
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      30
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      11
    term
    Neutropenia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      87
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      42
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Thrombocytopenia
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      7
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Palpitations
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Ear and labyrinth disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Ear pain
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Endocrine disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Adrenal insufficiency
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      8
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Cataract
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Macular pigmentation
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      8
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Abdominal pain upper
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      72
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      22
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Constipation
Complete source fields
event Groups
  1. deaths Num Affected
    252
    deaths Num At Risk
    300
    description
    Participants received 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle and 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression.
    id
    EG000
    other Num Affected
    291
    other Num At Risk
    300
    serious Num Affected
    195
    serious Num At Risk
    300
    title
    Pomalidomide Plus Low-Dose Dexamethasone
  2. deaths Num Affected
    124
    deaths Num At Risk
    150
    description
    Participants received 40 mg dexamethasone (participants \> 75 years of age received 20 mg dexamethasone) administered by mouth once per day on Days 1 through 4, 9 through 12, and 17 through 20 of a 28-day cycle until disease progression, or until cross-over to pomalidomide. Data are up to the time of cross-over.
    id
    EG001
    other Num Affected
    143
    other Num At Risk
    150
    serious Num Affected
    80
    serious Num At Risk
    150
    title
    High-Dose Dexamethasone
  3. deaths Num Affected
    8
    deaths Num At Risk
    11
    description
    Participants initially randomized to high-dose dexamethasone (HD-Dex) crossed over to receive 4 mg pomalidomide administered by mouth on Days 1-21 of each 28-day treatment cycle, with or without low-dose dexamethasone (40 mg for participants ≤ 75 years or 20 mg for participants \> 75 years of age, administered orally once per day on Days 1, 8, 15, and 22 of each 28-day cycle) at the discretion of the investigator. Data include AEs that occurred after cross-over to pomalidomide.
    id
    EG002
    other Num Affected
    11
    other Num At Risk
    11
    serious Num Affected
    4
    serious Num At Risk
    11
    title
    HD-Dex / Pomalidomide
frequency Threshold
5
other Events
  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      159
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      77
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      4
      num At Risk
      11
    term
    Anaemia
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      40
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      8
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Leukopenia
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      13
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      8
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Lymphopenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      155
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      30
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      5
      num At Risk
      11
    term
    Neutropenia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      87
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      42
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Thrombocytopenia
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      7
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Palpitations
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Ear and labyrinth disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Ear pain
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Endocrine disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Adrenal insufficiency
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      8
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Cataract
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Eye disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Macular pigmentation
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      8
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      3
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Abdominal pain upper
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Gastrointestinal disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      72
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      22
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      1
      num At Risk
      11
    term
    Constipation
serious Events
  1. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      10
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      7
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Anaemia
  2. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Blood disorder
  3. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      19
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Febrile neutropenia
  4. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Haemorrhagic anaemia
  5. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Hyperviscosity syndrome
  6. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      10
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Neutropenia
  7. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      2
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      2
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Pancytopenia
  8. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Blood and lymphatic system disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      6
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      4
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Thrombocytopenia
  9. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      0
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Angina pectoris
  10. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      7
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Atrial fibrillation
  11. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      1
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Atrial flutter
  12. assessment Type
    SYSTEMATIC_ASSESSMENT
    organ System
    Cardiac disorders
    source Vocabulary
    MedDRA 19
    stats
    1. group Id
      EG000
      num Affected
      1
      num At Risk
      300
    2. group Id
      EG001
      num Affected
      0
      num At Risk
      150
    3. group Id
      EG002
      num Affected
      0
      num At Risk
      11
    term
    Atrial tachycardia
time Frame
From first dose of study drug through to 30 days after the last dose as of the end of the study (29 August 2017); maximum time on treatment was 297, 269, and 239 weeks in the Pomalidomide + LD-Dex, HD-Dex, and cross-over groups respectively.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice